Cantor Fitzgerald initiated coverage on Celcuity with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for CELC
Across the 28 sessions after earlier CELC headlines, the stock closed higher 17 times and lower 11 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CELC | SPY |
|---|---|---|---|
| Oct 5, 2026 | Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 | +2.1% | +0.7% |
| Oct 2, 2026 | Celcuity Appoints David Gryska To Its Board Of Directors | -4.0% | +0.7% |
| Sep 30, 2026 | Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States | +2.8% | -0.2% |
| Sep 17, 2026 | Analyst initiated coverage on Celcuity with a new price target | +2.8% | +1.1% |
| Sep 1, 2026 | Celcuity To Participate in Upcoming Investor Conferences | +3.3% | -0.7% |
| Aug 26, 2026 | Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer | +3.0% | +0.0% |
Quantisnow market dataNASDAQ
CELC
Celcuity Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2017
Get push alerts for CELC
Full CELC profile on Quantisnow Follow CELC and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time